Pre-clinical data on HOOKIPA's arenaviral immunotherapeutic in melanoma published in Nature Communications

Pre-clinical data on HOOKIPA's arenaviral immunotherapeutic in melanoma published in Nature Communications

Publication date: Aug 06, 2021

Importantly, a single, local injection of the vector into the tumor also led to systemic immune responses, significantly reducing the number of lung metastases. HOOKIPA’s HB-300 program for prostate cancer also uses the LCMV and PICV arenaviral backbones directed against three validated antigens for prostate cancer: PAP, PSA, and PSMA. HOOKIPA Forward Looking Statements Certain statements set forth in this press release constitute -forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. HOOKIPA’s pipeline includes ongoing clinical trials in Human Papilloma Virus 16-positive cancers and Cytomegalovirus, as well as preclinical research in prostate cancer, HIV and Hepatitis B. HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. HOOKIPA is evaluating its single-vector and alternating 2-vector technologies in cancer in an ongoing Phase 1/2 clinical trial with HB-201 and HB-202.

Concepts Keywords
Arenaviral Antibodies
Austria Immunotherapeutics
Cancernew Melanoma
Killer Tumor microenvironment
Mice Tumor antigen
Oncolytic virus
Cancer immunotherapy
Clinical medicine
Class immunotherapeutics
Stage biopharmaceutical
Social media channels


Type Source Name
disease MESH infection
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH Hepatitis B
pathway KEGG Hepatitis B
drug DRUGBANK Coenzyme M
disease MESH development
disease MESH COVID-19
pathway KEGG Prostate cancer
disease MESH prostate cancer
disease MESH head and neck cancer
drug DRUGBANK Tropicamide
disease MESH metastases
drug DRUGBANK Spinosad
disease MESH Lymphocytic choriomeningitis
drug DRUGBANK Nonoxynol-9
disease MESH melanoma
pathway KEGG Melanoma
disease MESH tumor

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *